MEF2D Antibody (monoclonal) (M02)
Mouse monoclonal antibody raised against a partial recombinant MEF2D.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND

Application
| WB, IF |
|---|---|
| Primary Accession | Q14814 |
| Other Accession | NM_005920 |
| Reactivity | Human |
| Host | mouse |
| Clonality | Monoclonal |
| Isotype | IgG2a Kappa |
| Clone Names | 3A11 |
| Calculated MW | 55938 Da |
| Gene ID | 4209 |
|---|---|
| Other Names | Myocyte-specific enhancer factor 2D, MEF2D |
| Target/Specificity | MEF2D (NP_005911.1, 256 a.a. ~ 351 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Dilution | WB~~1:500~1000 IF~~1:50~200 |
| Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
| Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Precautions | MEF2D Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
COMMON VARIANTS IN 40 GENES ASSESSED FOR DIABETES INCIDENCE AND RESPONSE TO METFORMIN AND LIFESTYLE INTERVENTIONS IN THE DIABETES PREVENTION PROGRAM. Jablonski KA, et al. Diabetes, 2010 Aug 3. PMID 20682687.Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.Dual roles for MEF2A and MEF2D during human macrophage terminal differentiation and c-Jun expression. Aude-Garcia C, et al. Biochem J, 2010 Sep 1. PMID 20590529.Regulation of cardiomyocyte Glut4 expression by ZAC1. Czubryt MP, et al. J Biol Chem, 2010 May 28. PMID 20363751.Association of genetic variants with hemorrhagic stroke in Japanese individuals. Yoshida T, et al. Int J Mol Med, 2010 Apr. PMID 20198315.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.





Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.




